Search PubMed⌕ Search

Biomedical subjects

D V Parke

Publications and source records attributed to D V Parke.

At least 109 records · Page 6Linked to original sources

Ligand-complex formation between cytochromes P-450 and P-448 and methylenedioxyphenyl compounds.

The formation of ligand complexes between hepatic microsomal cytochrome P-450 and safrole, isosafrole and other methylenedioxyphenyl compounds was studied in vivo and in vitro in rats pretreated with either phenobarbital or 3-methylcholanthrene. Both the phenobarbital-induced cytochrome P-450 and the 3-methylcholanthrene-induced cytochrome P-448 metabolically convert safrole, isosafrole, and those metabolites possessing an intact methylenedioxy group, to reactive metabolites which then interact with the cytochromes to form ligand complexes. Formation of these ligand complexes was accompanied by loss of mixed-function oxidase activities, and dissociation of the complexes with the type I substrate biphenyl restored activities. Safrole and, to a lesser extent, 1'-hydroxysafrole formed complexes in vivo when administered to phenobarbital-pretreated rats; none was obtained with epoxysafrole. However, when administered to 3-methylcholanthrene-pretreated animals all three compounds formed complexes, safrole being the least effective. Epoxysafrole and 1'-hydroxysafrole administered to phenobarbital-pretreated rats resulted in slight inhibition of the type I binding of safrole to liver microsomal P-450 in vitro; in contrast, with 3-methylcholanthrene-pretreated animals marked competitive inhibition was observed. This study shows that oxidation of the allyl chain of safrole analogues enhances their affinity for cytochrome P-448, but not for cytochrome P-450, and further demonstrates that these cytochromes possess distinctly different binding sites.

Animals↗

Beneficial short-term effects of unprocessed wheat bran on lipid and glucose metabolism in man.

Supplementation of the normal diets of seven healthy 18-22-year old male and female volunteers with 0.15 g unprocessed wheat bran/kg body weight/d for 6 weeks increased fibre consumption by 35 per cent without noticeably affecting the intake of other major nutrients. Fasting concentrations of plasma total cholesterol, triglyceride and glucose were unchanged by wheat bran supplementation, whereas HDL-cholesterol was increased and LDL-cholesterol decreased by 46 per cent and 25 per cent respectively after 6 weeks. Glycosylated haemoglobin was decreased by 18 per cent, 27 per cent and 45 per cent after 2, 4 and 6 weeks. The results illustrate the potential value of consuming relatively small amounts of unprocessed wheat bran for the promotion of health and treatment of certain metabolic diseases in man.

Adolescent↗

Determination of cytochrome P-448 activity in biological tissues.

Three enzymes used for the determination of cytochrome P-448 activity, namely aryl hydrocarbon hydroxylase, biphenyl 2-hydroxylase and ethoxyresorufin O-de-ethylase, were evaluated with respect to their specificity, sensitivity and inducibility. Purified cytochrome P-448 (LM4), but not cytochrome P-450 (LM2), catalysed the O-de-ethylation of ethoxyresorufin in a reaction that was markedly inhibited by 9-hydroxyellipticine. After the administration of 3-methylcholanthrene to rats all three activities were induced, the extent of induction being highest for ethoxyresorufin O-de-ethylase. Administration of very small doses of benzo[a]pyrene (50 micrograms/kg) to rats to induce cytochrome P-448 specifically increased only the O-de-ethylation of ethoxyresorufin. 3-Hydroxybenzo[a]pyrene, the major metabolite determined by the aryl hydrocarbon hydroxylase assay, undergoes further NADPH-dependent oxygenation leading to loss of fluorescence. On the basis of these observations and those by other workers, we conclude that ethoxyresorufin O-de-ethylase provides the most specific, sensitive and reproducible means of determining cytochrome P-448 activity.

Animals↗

Single-dose pharmacokinetics of perhexiline administered orally to humans.

A high-performance liquid chromatographic method for the simultaneous determination of perhexiline and its major metabolites, the cis- and trans-monohydroxyperhexilines M1 and M3, respectively, in human plasma or urine has been developed. Perhexiline and its metabolites are extracted from plasma or urine and derivatized with 1-fluoro-2,4-dinitrobenzene. The extracted dinitrophenyl derivatives of drug and metabolites are separated on a Spherisorb S5 ODS column by gradient elution. The limits of detection for perhexiline and its monohydroxy metabolites were 15 and 3 ng/ml, respectively. The inter-assay coefficients of variation for 100 ng/ml perhexiline, 100 ng/ml M1 and 400 ng/ml M3 were 10.5, 7.6 and 5.6%, respectively (n = 9). The method has been employed in a limited kinetic study with five healthy adult male volunteers who received 150-mg and 300-mg Pexid tablets at an interval of one week. In four subjects perhexiline exhibited marked first pass effects, with plasma M1 levels higher than unchanged perhexiline; in the urine M1 was the predominant metabolite except in one subject who had higher M3 than M1 in the 300-mg Pexid study. The fifth subject exhibited a defective capacity to hydroxylate perhexiline; M1 and M3 were not detectable in plasma, and the urinary excretion of the monohydroxyperhexilines was relatively less, with M3 present in higher amounts than M1.

Administration, Oral↗

Active metabolites in toxicology: the role of cytochrome P-448 and flavoprotein oxidases.

The activation of toxic chemicals and carcinogens into reactive intermediates involves oxygenation in hindered positions of the molecule, by cytochrome P-448 (LM4), flavoprotein oxidoreductases, or transoxygenation during prostaglandin biosynthesis. Cytochrome P-450 (LM2) does not oxygenate in hindered positions and therefore generally detoxicates carcinogens and toxic chemicals. Cytochrome P-448 has a different active site from cytochrome P-450, which enables it to oxygenate substrates in conformationally-hindered positions.

Animals↗

Metabolism of the carbamate herbicide, asulam, in the rat.

The metabolism of [ring-14C]asulam, a systemic herbicide highly effective against bracken, has been studied in rats. Most of the radioactivity (76-100% dose) administered orally or intravenously is excreted in the urine in 24 h as unchanged asulam (61-74% dose), N4-acetylasulam (8-14%) and N4-acetylsulphanilamide (0.1-2.6%). Small amounts of radioactivity (0.3-7.4% dose) were present in the faeces, only traces (0.2-0.3%) were excreted in the bile, and no significant 14CO2 was detected. Perfusion of rat liver with 14C-asulam resulted in more extensive metabolism. Total amounts present in perfusate (81% total), bile (1%) plus liver (14%) were 23.1% for unchanged asulam, 25.7% for acetylasulam, less than 1% for acetylsulphanilamide, and 4.5% as conjugates of asulam and acetylasulam, together with several other unidentified metabolites. Asulam is acetylated more readily than sulphanilamide, by rat-liver homogenate, and the highest enzyme activity was associated with the mitochondrial fraction (2.4 pmol/mg protein per min). Although not hydroxylated by rats in vivo, evidence was obtained for the hydroxylation of asulam by rat-liver microsomal preparations in vitro.

Acetylation↗

The mechanism of action of phenformin in starved rats.

The ability of phenformin to lower the blood glucose concentration after an intraperitoneal glucose load, with a concomitant increase in blood lactate concentration, indicated that the drug was increasing the rate of anaerobic glycolysis. The results of experiments in which glucose and gluconeogenic precursors were given to starved rats were explained by a hypothesis for the mechanism of action of phenformin involving inhibition of certain NAD+-dependent dehydrogenases. Substrates with NAD+-linked oxidations could be discriminated from those, like succinate, with FAD-linked oxidations, and succinate may be of use in the treatment of clinical lacticacidosis caused by biguanide drugs.

Animals↗

Effect of deuteration of imipramine on its pharmacokinetic properties in the rat.

Imipramine was specifically deuterated in either both aromatic rings or in the N-methyl group, or in both positions, and the pharmacokinetic properties of the products were determined in the rat and compared with those of the non-deuterated analogue. Deuteration of imipramine resulted in a small but significant isotope effect on N-demethylation while aromatic hydroxylation was unaffected. This isotope effect led to a slower rate of systemic clearance, a longer half-life and, when orally administered, enhanced bioavailability. Urinary excretion of didesmethylimipramine-d4, following oral administration of imipramine-d7, was significantly lower than the excretion of didesmethylimipramine following administration of unlabelled imipramine, indicating inhibited demethylation. Similarly, the urinary excretion of desmethylimipramine-d4, didesmethylimipramine-d4 and 2-hydroxydesmethylimipramine-d4 were lower than for the corresponding unlabelled or d7-analogues, indicating the stability of the N-CD3 group. Deuteration had no effect on the pharmacological properties of imipramine as determined in this study.

Animals↗

Studies on the degranulation test for carcinogens.

The radiometric assay of degranulation of the hepatic endoplasmic reticulum by chemical carcinogens has been re-examined. Both 1,2,3,4,- and 1,25,6-dibenzanthracenes caused degranulation of rough membranes in vitro; with acetamidofluorenes and naphthylamines the carcinogenic analogues caused moderately greater degranulation. Degranulation by 1,2,3,4-dibenzantracene was rapid and was maximal after 5 min incubation. Pretreatment of animals with phenobarbital or methylcholanthrene increased the fraction of rough membranes, but these were not fully granulated. The assay is limited in specificity and sensitivity because the 1.35 M sucrose gradient does not effectively separate rough and smooth membranes, and sedimented membranes are contaminated with aggregates of free ribosomes.

1-Naphthylamine↗

A comparison of the protective effects of N-acetyl-cysteine and S-carboxymethylcysteine against paracetamol-induced hepatotoxicity.

The protective effect of the sulphur-containing amino acids N-acetyl-cysteine and S-carboxymethylcysteine against paracetamol-induced hepatotoxicity was evaluated in the hamster by biochemical and histological methods. Of the animals receiving paracetamol alone 25% died within 24 h following administration. All surviving animals showed acute hepatocellular injury and marked loss of cytochrome P-450 and hepatic mixed-function oxidase activities. Simultaneous administration of N-acetylcysteine decreased the mortality rate, partly prevented the paracetamol-induced liver damage and partly restored enzyme activities. Simultaneous administration of S-carboxymethylcysteine with paracetamol afforded no protection. Kidneys from all animals were histologically normal. Human liver microsomes and liver microsomes from 3-methylcholanthrene-pretreated hamsters metabolished paracetamol to intermediate(s) that bind covalently to microsomal proteins. The rate of covalent binding was inhibited markedly by N-acetylcysteine and to a lesser extent by S-carboxylmethylcysteine.

Acetaminophen↗

Species variation in the metabolic activation of paracetamol to toxic intermediates: role of cytochromes p-450 and p-448.

The metabolic activation of paracetamol to reactive intermediate(s) covalently bound to microsomes was investigated using microsomal preparations from various laboratory animals and man. The hamster and mouse, in contrast to the rat, were good activators. Microsomal preparations from 3-methylcholanthrene (3MC)-induced hamsters were markedly more efficient in activating paracetamol than similar preparations from phenobarbital (PB)-induced animals. The activation of paracetamol by the 3MC-induced hamster preparations was inhibited by 9-hydroxyellipticine but not by metyrapone. These results indicate that hepatic cytochrome P-448 but not cytochrome P-450 can convert paracetamol to reactive intermediate(s) which bind covalently to microsomal proteins.

Acetaminophen↗

Effect of some beta-adrenergic blocking agents on tissue guanylate cyclase and cyclic nucleotides in the rat.

Pretreatment of rats with the beta-adrenergic blocking agents, atenolol, practolol, pronethalol and propranolol, at a dosage of 150 mg/kg/day for 5 days, produced marked increases in guanylate cyclase activity in the liver, gastric and intestinal mucosae, but with concomitant decreases in cyclic GMP levels. The ratios of cAMP/cGMP in each of the tissues were not changed significantly from control values after pretreatment with these drugs. These observations indicate that any oncogenicity seen with beta-blocking agents is not due to the common pharmacological action of beta-adrenoreceptor blockade.

Adrenergic beta-Antagonists↗

Studies on the possible mutagenicity of beta-adrenergic blocker drugs.

The mutagenic potential of nine beta-adrenergic blocking agents was investigated in the Ames and micronucleus tests. None of the drugs studied showed any mutagenic response in the Ames test, either in the presence or in the absence of an activation system. At the highest concentration oxprenolol and propranolol exhibited a bactericidal effect. In the micronucleus test the same drugs showed a weak, but statistically non-significant response, but only at the highest doses. It is concluded that there is no overt mutagenic or carcinogenic potential associated with beta-adrenergic blocking drug activity.

Adrenergic beta-Antagonists↗

Studies on the substrate-binding sites of liver microsomal cytochrome P-448.

The interaction of substrates of the microsomal mixed-function oxidases with cytochromes P-450 and P-448 was investigated by using liver microsomes from rats pretreated with phenobarbital or 3-methylcholanthrene, and with purified forms of the cytochromes isolated from rabbit liver. The two forms of the cytochrome have different substrate specificities; cytochrome P-450 has one type 1 substrate-binding site that can accommodate a large variety of substrates, but in contrast cytochrome P-448 may possess two type 1 substrate-binding sites, one of which is different to that of cytochrome P-450 in that it shows a specificity for substrates such as safrole and 9-hydroxy-ellipticine. These findings explain why the two forms of the cytochrome have different substrate specificities and play contrasting roles in the activation and deactivation of xenobiotics.

Animals↗

Inhibition of gastrointestinal mucosal glycoprotein synthesis by the beta-adrenergic blocking drug, practolol.

The effect of administration of practolol and other beta-blocking agents on gastrointestinal mucosal glycoprotein synthesis was studied in the rat. Practolol, at a dose of 50 mg/kg, inhibited the incorporation of N-acetylglycosamine into gastric mucosal glycoproteins, while acebutolol, atenolol, pronethalol and propranolol had no inhibitory effect, even at a dose of 200 mg/kg. In addition, practolol inhibited the incorporation of N-acetylneuraminic acid, D-fucose and L-serine into gastric mucosal glycoproteins, while the other beta-blocking agents had no effect. Administration of practolol caused no significant change in the rate of incorporation of glycoprotein precursors into intestinal mucosal glycoproteins. These results indicate that of the beta-blocking drugs studied, inhibition of glycoprotein synthesis is associated only with practolol and is independent of its beta-blocking effect.

Adrenergic beta-Antagonists↗